ERS’s collaborative licensing approach promotes widespread adoption of CRISPR/Cas9 technology.
Non-exclusive licenses are available to companies involved in development and commercialization of CRISPR/Cas9 technology, products, and services.
Licenses are available in a wide range of fields
- Pharmaceutical & Biotechnology
- CROs, CMOs & Tool Providers
- Companion Animal & Veterinary Applications
- Agriculture & Livestock applications
- Industrial & Synthetic Biology Applications